| Literature DB >> 27070144 |
Jennifer P Stevens1,2,3, Kathy Baker4, Michael D Howell5,6, Robert B Banzett2,3.
Abstract
BACKGROUND: Dyspnea (breathing discomfort) can be as powerfully aversive as pain, yet is not routinely assessed and documented in the clinical environment. Routine identification and documentation of dyspnea is the first step to improved symptom management and it may also identify patients at risk of negative clinical outcomes.Entities:
Mesh:
Year: 2016 PMID: 27070144 PMCID: PMC4829144 DOI: 10.1371/journal.pone.0152601
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Prevalence of patients experiencing burdensome dyspnea and pain at the time of initial patient assessment (Study 1) and at any time during the hospital stay (Study 2).
Univariate associations with first dyspnea score (both cohorts) and worst dyspnea score (second cohort), dichotomized into <4 and > = 4.
Confidence intervals calculated using Wald confidence limits for binomial proportions.
| Pilot Study 1—Initial Patient Assessment | Pilot Study 2 –Every Shift Assessment | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Current dyspnea, first shift (95% CI) | p-value | Worst dyspnea, any shift (95% CI) | p-value | Current dyspnea, first shift (95% CI) | p-value | ||||
| <4 | > = 4 | <4 | > = 4 | <4 | > = 4 | ||||
| N | 504 | 77 | 310 | 57 | 353 | 12 | |||
| % female | 46 (42–51) | 53 (42–64) | 0.26^ | 47 (42–53) | 56 (43–69) | 0.23^ | 48 (43–54) | 66 (40–93) | 0.21^ |
| mean age | 62 (60–63) | 63 (59–66) | 0.55** | 62(60–64) | 68 (64–71) | 0.017** | 63 (61–65) | 63 (52–74) | 0.99** |
| % nonwhite | 23 (19–26) | 35 (24–46) | 0.02^ | 44 (39–50) | 44 (31–57) | 0.97^ | 44 (39–49) | 50 (22–78) | 0.68^ |
| CHF | 16 (13–19) | 34 (23–44) | 0.002^ | 17 (13–21) | 40 (28–53) | <0.0001 | 20 (16–25) | 33 (7–60) | 0.28* |
| Valve disease | 6 (4–8) | 10 (4–17) | 0.19^ | 7 (4–10) | 2 (0–5) | 0.22* | 6 (3–8) | 8 (0–24) | 0.53* |
| Pulmonary circulation | 5 (3–6) | 12 (5–19) | 0.03* | 4 (2–6) | 16 (6–25) | 0.003* | 5 (3–8) | 25 (1–50) | 0.03* |
| Paralysis | <1 (0–2) | 4 (0–8) | 0.08* | 1 (0–3) | 2 (0–9) | 0.58* | 1 (0–2) | 8 (0–24) | 0.15* |
| Other neurologic disease | 5 (3–7) | 8 (2–14) | 0.27^ | 7 (4–10) | 13 (4–21) | 0.19* | 8 (5–10) | 17 (0–38) | 0.25* |
| COPD | 14 (11–18) | 29 (18–39) | 0.002^ | 14 (10–18) | 30 (18–42) | 0.004* | 16 (12–20) | 33 (7–60) | 0.12* |
| DM | 23 (20–27) | 18 (10–27) | 0.31^ | 18 (14–22) | 21 (10–32) | 0.54^ | 18 (14–22) | 17 (0–38) | 1* |
| DM with compli-cations | 5 (3–7) | 10 (4–17) | 0.06* | 7 (4–10) | 5 (0–11) | 1* | 7 (4–9) | 0 (0–0) | 1* |
| Hypo-thyroidism | 12 (9–14) | 14 (6–22) | 0.48^ | 11 (8–15) | 9 (1–16) | 0.6^ | 11 (8–14) | 8 (0–24) | 1* |
| Renal failure | 15 (12–18) | 29 (18–39) | 0.003^ | 14 (10–18) | 26 (15–38) | 0.02* | 16 (12–20) | 17 (0–38) | 1* |
| Obesity | 7 (5–9) | 5 (0–10) | 0.53^ | 12 (9–16) | 9 (1–16) | 0.47 | 12 (9–16) | 0 (0–0) | 0.37* |
| Chronic blood loss | <1 (0–1) | 3 (0–6) | 0.05* | 2 (0–3) | 0 (0–0) | 1* | 1 (0–3) | 0 (0–0) | 1* |
| Alcohol abuse | 3 (2–5) | 8 (2–14) | 0.06* | 4 (2–6) | 4 (0–8) | 1* | 4 (2–6) | 8 (0–24) | 0.40* |
| Drug abuse | 2 (1–3) | 3 (0–6) | 0.66* | 1 (0–3) | 9 (1–16) | 0.006* | 2 (1–4) | 17 (0–38) | 0.04* |
| Psychotic illness | 3 (1–4) | 4 (0–8) | 0.72* | 3 (1–5) | 2 (0–5) | 1* | 3 (1–5) | 0 (0–0) | 1* |
| Depression | 16 (13–19) | 14 (6–22) | 0.75^ | 15(11–19) | 12 (4–21) | 0.69* | 15 (11–19) | 8 (0–24) | 1* |
| Chronic hyper-tension | 61 (56–65) | 58 (47–69) | 0.73^ | 59 (53–64) | 61 (49–74) | 0.68^ | 58 (53–64) | 75 (51–100) | 0.25^ |
| % emergent | 88 (85–91) | 100 (100–100) | 0.001^ | 89 (86–93) | 96 (92–100) | 0.09^ | 90 (87–93) | 100 | 0.61* |
| LAPS2 score | 31 (29–34) | 41 (35–47) | 0.002** | 30 (27–32) | 42 (36–48) | 0.0003** | 31 (29–33) | 47 (34–59) | 0.03** |
| LOS | 3.3 (3.0–3.6) | 4.5 (3.0–6.2) | 0.13** | 4.6 (4.2–5.1) | 8.1 (6.2–9.9) | <0.0005** | 5.2 (4.7–5.6) | 5.3 (2.1–8.4) | 0.94** |
| ICU LOS | <0.2 (0.05–0.26) | <0.2 (0–0.85) | 0.33** | 0.23 (.13-.33) | 0.82 (.17–1.5) | 0.08** | <0.5 (.19-.47) | 0 (0–0) | <0.0001** |
| Total charges ($) | 23,633 (21,318–25,949) | 26,658 (16,241–37,076) | 0.57** | 26,015 (22,764–29,266) | 43,586 (30,744–56,428) | 0.01** | 29,075 (25,549–32602) | 19,451 (7,844–31,059) | 0.33** |
| % readmitted at 30 days | 6 (7–12) | 9 (3–16) | 1^ | 28 (23–33) | 30 (18–42) | 0.8^ | 30 (23–33) | 42 (14–70) | 0.33* |
P-values marked with * indicate differences evaluated using Fisher's Exact test, ^ indicate chi-sq. tests, and ** indicate Student’s t-test
Fig 2Three example patterns of dyspnea recorded once per nursing shift.
Patient 1 presented with a dyspnea score of 8, Patient 2 with a score of 5 and Patient 3 with a score of 1. All of these patients had a length of stay more than 8 days, longer than average. (Study 2)
Fig 3Univariable comparisons of risk of combined negative outcome related to measurements of dyspnea.
Panel A–Pilot Study 1: (a) measurements of current dyspnea on admission and (b) measurements of exertional dyspnea prior to admission; Panel B–Pilot Study 2: (a) measurements of current dyspnea during first nursing shift and (b) measurements of any elevated dyspnea throughout the hospitalization. Error bars represent 95% confidence intervals calculated using Wald confidence limits for binomial proportions; tests of difference were performed using chi-squared tests with the exception of Pilot Study 2, upper right panel, which used Fisher’s exact test given small cell sizes.